Gastric bypass surgery in @entity28 XXXX with @entity6 : a 1-year follow-up of 58 cases in Chinese.

@entity1 @entity6 @entity28 @entity164 @entity413
OBJECTIVE: To investigate the clinical efficacy of gastric bypass surgery in @entity28 @entity1 with @entity164 2 @entity6 . METHODS: Clinical data of 58 @entity28 @entity1 with @entity164 2 @entity6 (body mass index range from 22.1-25.8 kg/m(2)) were collected one year after gastric bypass surgery. Collected parameters included fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin, fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1. The insulin resistance index (HOMA-IR = fasting plasma @entity413 * fasting serum insulin/22.5) and the body mass index were calculated. RESULTS: Of the 58 @entity1 , 48 had stopped taking all hypoglycemic drug treatments and had achieved complete remission (82.8%). Seven @entity1 were unable to completely withdraw from hypoglycemic agents, although their intake of drugs was reduced at least 50% compared to pre-surgical values (12.0%). Three of the cases showed no significant change in blood @entity413 after surgery (5.2%). In addition, values for fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin and HOMA-IR significantly decreased after surgery. Values for fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1 significantly increased after surgery, and the body mass index at the sixth post-operative month were significantly lower than pre-operative. CONCLUSION: For @entity28 @entity1 with @entity164 2 @entity6 , gastric bypass surgery has a significant clinical effect. Potential mechanisms include improvements in insulin resistance and/or increased endogenous intestinal glucagon-like peptide-1 secretion leading to improved insulin secretion.
